IL1RAP and cardiovascular disorder: In a phase I trial, nadunolimab as monotherapy treatment led to reductions in the levels of the cardiovascular risk factors CRP and IL-6, further arguing in favour of a cardiovascular benefit of IL1RAP blockade.67 Similar to canakinumab, administration of nadunolimab is associated with reduced levels of neutrophils.67 Phase I studies of CAN10, which does not promote ADCC, could potentially provide insights into its effects on inflammatory biomarkers relevant to cardiovascular disease as well as rates of adverse events.